American Bio Medica Corporation (ABMC) Research

American Bio Medica Corporation (ABMC) specializes in the development and distribution of lateral flow immunoassay tests, primarily designed for the rapid detection of drugs in both urine and oral fluid samples. Their extensive range of urine-based drug screening solutions includes the Rapid Drug Screen, capable of identifying between 2 and 10 substances; the RDS InCup, a convenient testing cup detecting 1 to 12 drugs; Rapid TOX, a cassette-based test for 1 to 10 drugs; and the Rapid TOX Cup II, another cup format that screens for 1 to 16 different drugs. Each product aims to swiftly determine the presence or absence of illicit substances. Furthermore, ABMC provides OralStat, an oral fluid drug test, available also in private-labeled versions. Beyond its proprietary offerings, the company acts as a distributor for various other products focused on detecting substances of abuse and identifying specific infectious diseases. The company extends its expertise to non-affiliated diagnostic firms, offering contract services that encompass the manufacturing, assembly, and packaging of diagnostic strips. Serving a diverse clientele, ABMC caters to the needs of rehabilitation and drug treatment centers, pain management clinics, general clinical settings, government agencies, and employment/workplace screening programs. Its operations span across the United States, Europe, the Asia Pacific region, and South America. Founded in 1986 as American Micro Media, Inc., the company adopted its current name, American Bio Medica Corporation, in September 1992. Its corporate headquarters are situated in Kinderhook, New York.

Open American Bio Medica Corporation (ABMC) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.